Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
- Sunder Mudaliar, MD1,2,
- Debra A. Armstrong, BA, RN, CCRC1,
- Annie A. Mavian, MD2,
- Robin O’Connor-Semmes, PHD3,
- Patricia K. Mydlow, BS3,
- June Ye, PHD3,
- Elizabeth K. Hussey, PHARMD3,
- Derek J. Nunez, MD3,
- Robert R. Henry, MD1,2 and
- Robert L. Dobbins, MD, PHD3⇓
- 1Medicine Service, Veterans Administration Medical Center, San Diego, California
- 2Department of Medicine, University of California San Diego, San Diego, California
- 3GlaxoSmithKline Research & Development, Research Triangle Park, North Carolina
- Corresponding author: Robert L. Dobbins,
OBJECTIVES Remogliflozin etabonate (RE), an inhibitor of the sodium-glucose transporter 2, improves glucose profiles in type 2 diabetes. This study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of RE in subjects with type 1 diabetes.
RESEARCH DESIGN AND METHODS Ten subjects managed with continuous subcutaneous insulin infusion were enrolled. In addition to basal insulin, subjects received five randomized treatments: placebo, prandial insulin, 50 mg RE, 150 mg RE, and mg RE 500.
RESULTS Adverse events and incidence of hypoglycemia with RE did not differ from placebo and prandial insulin groups. RE significantly increased urine glucose excretion and reduced the rise in plasma glucose concentration after oral glucose. RE reduced incremental adjusted weighted mean glucose (0–4 h) values by 42–49 mg/dL and mean glucose (0–10 h) by 52–69 mg/dL.
CONCLUSIONS RE can be safely administered with insulin in type 1 diabetes and reduces plasma glucose concentrations compared with placebo.
- Received March 15, 2012.
- Accepted May 23, 2012.
- © 2012 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.